For research and educational purposes only. Not medical advice.
Larazotide Reference
Educational, not medical advice reference for Larazotide: Immune, Recovery; regulatory status, evidence posture, source review, and schedule notes. Also know…
Reference summary
Peer-reviewed Phase 2b data (Leffler 2015) showed symptom improvement in celiac patients with persistent symptoms on a gluten-free diet. pepSmart presents larazotide only as trial-context educational content.
- Categories
- Immune, Recovery
- Aliases
- Larazotide acetate, AT-1001, INN-202
- Evidence posture
- human — Human trial data exist, but larazotide remains investigational and Phase 3 topline results have not yielded an approved product.
- Regulatory status
- Investigational. Larazotide acetate is a tight-junction regulator studied as an oral add-on to gluten-free diet in celiac disease. A Phase 3 trial (CeDLara) was conducted in the US; no FDA-approved drug label currently exists.
- Content review status
- investigational verified